{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T17:07:08Z","timestamp":1753895228461,"version":"3.41.2"},"reference-count":0,"publisher":"Wiley","issue":"4S3","license":[{"start":{"date-parts":[[2014,11,2]],"date-time":"2014-11-02T00:00:00Z","timestamp":1414886400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of the International AIDS Society"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Factors that have an effect on the rate of sustained virological response (SVR) in chronic hepatitis C (CHC) patients include: genotype of hepatitis C virus (HCV); level of HCV RNA replication and rate of its reduction in the course of treatment; original hepatic fibrosis level; genotype of Interleukin\u201028B (especially for Genotype 1 HCV \u2013 G1); daily ribavirin (RBV) dose. This study evaluated the effect of the HIV infection\u2010related factors on the SVR rate in HCV treatment in patients with concurrent infection (HIV\/HCV).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The follow\u2010up included 232 HIV\/HCV\u2010infected patients. Ninety\u2010nine of 232 patients with HIV\/HCV\u2010infection received antiretroviral therapy (ART) for at least three months before the initiation of the CHC treatment. Before the HCV therapy, the median of CD4+cells was 406\/mm<jats:sup>3<\/jats:sup> (with ART) and 507\/mm<jats:sup>3<\/jats:sup> (without ART). Patients received HCV treatment with pegylated interferon (PEG\u2010IFN) and RBV (1000\/12,000 mg\/day) during 24\u201348 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>SVR was received in 50% of patients with G1 HCV, and 80.1% of patients with Genotypes 2\/3 (G2\/3; p&lt;0.0001). The SVR rate in the group of patients without ART was reliably higher, 74.4% (with ART \u2013 58.6%; p=0.0053). No significant differences in the SVR rate (62.3% and 69.6%, accordingly) were detected after the differentiation of patients based on the initial absolute values of CD4+cells count (&lt;350 cells\/mm<jats:sup>3<\/jats:sup> and &gt;350 cells\/mm<jats:sup>3<\/jats:sup>). In 127 patients with the HIV\/HCV\u2010infection, the percentage of CD4+cells before the CHC treatment was &gt;25% and more (Group 1 [Gr. 1]), and in 105 patients \u226425% (Group 2 [Gr. 2]). The SVR rate for Gr. 1 patient was 74.6%, and for Gr. 2 patients \u201358.1% (p=0.0023). The SVR rate in patients with G1 HCV was 56.8% (Gr. 1) and 44.2% (Gr. 2; p=0.1095), whereas the rate for G2 and 3 was 85.5% and 71.7%, accordingly (p=0.0242). Forty patients in Gr. 1 and 59 patients in Gr. 2 received ART. The comparison of the SVR rate for these patients showed no significant differences: 60% and 57.6%, accordingly. SVR rate in the patients without ART demonstrated that for Gr.1 patients (CD4+&gt;25%) was reliably higher, 82.8% (compared to Gr.2 with 58.7%; p=0.0012).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Along with factors related to HCV and the patient, the SVR rate in the HCV treatment with PEG\u2010IFN and RBV may be affected in patients with the concurrent infection by the use of ART and original relative content of CD4+cells. The maximum SVR rate was achieved in the patients without ART and with the CD4+cells &gt;25% (baseline). When indicted, it is reasonable to provide HCV treatment to HIV\u2010infected patients as long as the percentage of CD4+cells remains high and there is no need of ART.<\/jats:p><\/jats:sec>","DOI":"10.7448\/ias.17.4.19635","type":"journal-article","created":{"date-parts":[[2014,11,3]],"date-time":"2014-11-03T08:30:34Z","timestamp":1415003434000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of HIV infection\u2010related factors on SVR rate in HCV treatment in HIV\u2010infected patients"],"prefix":"10.1002","volume":"17","author":[{"given":"Alexey","family":"Kravchenko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uliana","family":"Kuimova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,11,2]]},"container-title":["Journal of the International AIDS Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.7448%2FIAS.17.4.19635","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.7448\/IAS.17.4.19635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T17:09:54Z","timestamp":1695575394000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.7448\/IAS.17.4.19635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":0,"journal-issue":{"issue":"4S3","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.7448\/IAS.17.4.19635"],"URL":"https:\/\/doi.org\/10.7448\/ias.17.4.19635","archive":["Portico"],"relation":{},"ISSN":["1758-2652","1758-2652"],"issn-type":[{"type":"print","value":"1758-2652"},{"type":"electronic","value":"1758-2652"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"2014-11-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"19635"}}